July / August #83 : Spin Doctors - by Denny Lee

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Once Upon A Time...

Young At Heartland

The Lying Game

Life vs. Meth

This Is Only a Test

Mbeki's 180

Spin Doctors

Soda Wars

Iran Runs

New Friend

Sex Crimes

Got Milk? Get Meds

Got His Goat

Monkey C

Mind Trip

Beach Reads

Memory Lane

Face the Music

Failure Is Sweet

Who Done It

Defensive Tackle

Under the Sun

Cave Kava

Relayed Reaction

Habit Helpers

Ticked & Stoned

Rated X5

Vax Populi

TB or Not TB

IV Leader

Flower Children


Drug Interactions

Dubya Trouble

Publisher's Letter


Reed Represents

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July / August 2002

Spin Doctors

by Denny Lee

Most media stories about skyrocketing drug prices boil down to this: Consumer advocates blame the cost on corporate greed at the expense of human lives; drug-makers reply that they need healthy profits to fund the high-risk R&D for lifesaving meds.

In April, the he said, she said resurfaced when the annual Fortune 500 list was announced, and drug-makers again ranked as the most profitable sector, edging out even financial firms at raking in cash. For every dollar of sales in 2001, Big Pharma made 18.5 cents in profit, compared to banks' 13.5.

With law-makers calling for price controls, the industry's P.R. machine went on the offensive, and The New York Times and The Wall Street Journal ran pieces with surprising headlines about shrinking profits ahead. Despite years of massive earnings, Pharma is fretting over three negative trends: no blockbuster drugs in the pipeline, brand-name drugs soon to go off-patent and generics eating away at sales. Giants such as Eli-Lilly & Co. reported a 22 percent drop in profits in the first quarter.

"We point to these challenges," said Jeff Trewhitt, a spokesperson for the lobbying group Pharmaceutical Research and Manufacturers of America, "and say that we should avoid price controls because they hurt innovation." It seems to be a case of old whines in new bottles.

But do sliding profits really mean a drier pipeline? Activists automatically shake their heads. "They'd like us to believe their record profits will be reduced, and therefore efforts to restrain prices will compromise R&D," said Ron Pollock, head of Families USA, a consumer health group. James Love, a health advocate at Public Citizen, said the cash-rich companies protest too much. "When they talk about 'lower profits,' they are still making billions," he said. But at press time, with Bristol-Myers Squibb and bankruptcy in the same headlines, one thing was clear: The old Pharma story was due for a revision.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.